MARVELD1 inhibited cell proliferation and enhance chemosensitivity via increasing expression of p53 and p16 in hepatocellular carcinoma

Cancer Science

Volumn 103, Issue 4, 2012, Pages 716-722

  Yu, Youtao ^a,b   Zhang, Yubao ^b   Hu, Jianran ^a   Zhang, Hao ^a   Wang, Shan ^a   Han, Fang ^a   Yue, Lei ^a   Qu, Youpeng ^a   Zhang, Yao ^a   Liang, Hongjian ^a   Nie, Huan ^a   Li, Yu ^a  

^a HARBIN INSTITUTE OF TECHNOLOGY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

10 HYDROXYCAMPTOTHECIN; 5 AZA 2' DEOXYCYTIDINE; CYCLIN D1; EPIRUBICIN; MARVELD1 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN; PROTEIN P16; PROTEIN P53; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; GENE DELETION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METHYLATION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; GENE DOSAGE; GENES, P16; GENES, P53; HUMANS; LIVER NEOPLASMS; MEMBRANE PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; RNA, SMALL INTERFERING; UP-REGULATION;

EID: 84862797816     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02220.x     Document Type: Article

References (29)

1. Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002; 122: 1609-19.
2. Poon D, Anderson BO, Chen LT et al. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009; 10: 1111-8.
3. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-50.
4. Yuen MF, Tanaka Y, Fong DY et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009; 50: 80-8.
5. Chen KF, Yeh PY, Yeh KH et al. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res 2008; 68: 6698-707.
6. Block TM, Mehta AS, Fimmel CJ et al. Molecular viral oncology of hepatocellular carcinoma. Oncogene 2003; 22: 5093-107.
7. Bruix J, Boix L, Sala M et al. Focus on hepatocellular carcinoma. Cancer Cell 2004; 5: 215-9.
8. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006; 6: 674-87.
9. Cancer. World Health Organization. February 2009. [Cited 10 Feb 2009] Available from URL: .
10. Kerr SH, Kerr DJ. Novel treatments for hepatocellular cancer. Cancer Lett 2009; 286: 114-20.
11. Sterpetti P, Marucci L, Candelaresi C et al. Cell proliferation and drug resistance in hepatocellular carcinoma are modulated by Rho GTPase signals. Am J Physiol Gastrointest Liver Physiol 2006; 290: G624-32.
12. Hatta M, Nagai H, Okino K et al. Down-regulation of members of glycolipid-enriched membrane raft gene family, MAL and BENE, in cervical squamous cell cancers. J Obstet Gynaecol Res 2004; 30: 53-8.
13. Luning Shao, Yan Cui, Hongyu Li et al. CMTM5 exhibits tumor suppressor activities and is frequently silenced by methylation in carcinoma cell lines. Clin Cancer Res 2007; 13: 5756-62.
14. Yu Wang, Jisheng Li, Yan Cui et al. CMTM3, located at the critical tumor suppressor locus 16q22.1, is silenced by CpG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis. Cancer Res 2009; 69: 5194-201.
15. Mimori K, Shiraishi T, Mashino K et al. MAL gene expression in esophageal cancer suppresses motility, invasion and tumorigenicity and enhances apoptosis through the Fas pathway. Oncogene 2003; 22: 3463-71.
16. Wang S, Li Y, Han F et al. Identification and characterization of MARVELD1, a novel nuclear protein that is down-regulated in multiple cancers and silenced by DNA methylation. Cancer Lett 2009; 282: 77-86.
17. Shi Y, Ding X, He ZH et al. Critical role of TRPC6 channels in G2 phase transition and the development of human esophageal cancer. Gut 2009; 58: 1443-50.
18. Han W, Lou Y, Tang V et al. Molecular cloning and characterization of chemokine-like factor 1 (CKLF1), a novel human cytokine with unique structure and potential chemotactic activity. Biochem J 2001; 357: 127-35.
19. Ikenouchi J, Sasaki H, Tsukita S et al. Loss of occludin affects tricellular localization of tricellulin. Mol Biol Cell 2008; 19: 4687-93.
20. Martín-Belmonte F, Martínez-Menárguez JA, Aranda JF et al. MAL regulates clathrin-mediated endocytosis at the apical surface of Madin-Darby canine kidney cells. J Cell Biol 2003; 163: 155-64.
21. Eissa S, Ali-Labib R, Khalifa A. Deletion of p16 and p15 genes In schistosomiasis associated bladder cancer (SABC). Clin Chim Acta 2000; 300: 159-69.
22. Jones CJ, Shaw JJ, Wyllie FS et al. High frequency deletion of the tumour suppressor gene P16'NK4a (MTSl) in human thyroid cancer cell lines. Mol Cell Endocrinol 1996; 116: 115-9.
23. Zhang Y, Wang R, Song H et al. Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett 2011; 303: 21-8.
24. Qureshi SA, Bashir MU, Yaqinuddin A. Utility of DNA methylation markers for diagnosing cancer. Int J Surg 2010; 8: 194-8.
25. Chambard JC, Lefloch R, Pouysségur J et al. ERK implication in cell cycle regulation. Biochim Biophys Acta 2007; 1773: 1299-310.
26. Meloche S, Pouysségur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition ERK1/2 MAP kinases in cell cycle control. Oncogene 2007; 26: 3227-39.
27. Arnold JL. The tumor suppressor genes. Annu Rev Biochem 1993; 62: 623-51.
28. Maofu Fu, Chenguang Wang, Zhiping Li et al. Cyclin D1: normal and abnormal functions. Endocrinology 2004; 145: 5439-47.
29. McCubrey JA, Steelman LS, Chappell WH et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007; 1773: 1263-84.